Strong Revenue Growth:
Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.
Investor Backing & Capital Strength:
Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.
Strategic Partnerships:
Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.
